Genomic surveillance during the first two years of the COVID-19 pandemic - country experience and lessons learned from Türkiye.

COVID-19 genomic surveillance next generation sequencing (NGS) public health severe acute respiratory syndrome coronavirus 2

Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2024
Historique:
received: 02 11 2023
accepted: 24 04 2024
medline: 10 6 2024
pubmed: 10 6 2024
entrez: 10 6 2024
Statut: epublish

Résumé

Türkiye confirmed its first case of SARS-CoV-2 on March 11, 2020, coinciding with the declaration of the global COVID-19 pandemic. Subsequently, Türkiye swiftly increased testing capacity and implemented genomic sequencing in 2020. This paper describes Türkiye's journey of establishing genomic surveillance as a middle-income country with limited prior sequencing capacity and analyses sequencing data from the first two years of the pandemic. We highlight the achievements and challenges experienced and distill globally relevant lessons. We tracked the evolution of the COVID-19 pandemic in Türkiye from December 2020 to February 2022 through a timeline and analysed epidemiological, vaccination, and testing data. To investigate the phylodynamic and phylogeographic aspects of SARS-CoV-2, we used Nextstrain to analyze 31,629 high-quality genomes sampled from seven regions nationwide. Türkiye's epidemiological curve, mirroring global trends, featured four distinct waves, each coinciding with the emergence and spread of variants of concern (VOCs). Utilizing locally manufactured kits to expand testing capacity and introducing variant-specific quantitative reverse transcription polymerase chain reaction (RT-qPCR) tests developed in partnership with a private company was a strategic advantage in Türkiye, given the scarcity and fragmented global supply chain early in the pandemic. Türkiye contributed more than 86,000 genomic sequences to global databases by February 2022, ensuring that Turkish data was reflected globally. The synergy of variant-specific RT-qPCR kits and genomic sequencing enabled cost-effective monitoring of VOCs. However, data analysis was constrained by a weak sequencing sampling strategy and fragmented data management systems, limiting the application of sequencing data to guide the public health response. Phylodynamic analysis indicated that Türkiye's geographical position as an international travel hub influenced both national and global transmission of each VOC despite travel restrictions. This paper provides valuable insights into the testing and genomic surveillance systems adopted by Türkiye during the COVID-19 pandemic, proposing important lessons for countries developing national systems. The findings underscore the need for robust testing and sampling strategies, streamlined sample referral, and integrated data management with metadata linkage and data quality crucial for impactful epidemiological analysis. We recommend developing national genomic surveillance strategies to guide sustainable and integrated expansion of capacities built for COVID-19 and to optimize the effective utilization of sequencing data for public health action.

Sections du résumé

Background UNASSIGNED
Türkiye confirmed its first case of SARS-CoV-2 on March 11, 2020, coinciding with the declaration of the global COVID-19 pandemic. Subsequently, Türkiye swiftly increased testing capacity and implemented genomic sequencing in 2020. This paper describes Türkiye's journey of establishing genomic surveillance as a middle-income country with limited prior sequencing capacity and analyses sequencing data from the first two years of the pandemic. We highlight the achievements and challenges experienced and distill globally relevant lessons.
Methods UNASSIGNED
We tracked the evolution of the COVID-19 pandemic in Türkiye from December 2020 to February 2022 through a timeline and analysed epidemiological, vaccination, and testing data. To investigate the phylodynamic and phylogeographic aspects of SARS-CoV-2, we used Nextstrain to analyze 31,629 high-quality genomes sampled from seven regions nationwide.
Results UNASSIGNED
Türkiye's epidemiological curve, mirroring global trends, featured four distinct waves, each coinciding with the emergence and spread of variants of concern (VOCs). Utilizing locally manufactured kits to expand testing capacity and introducing variant-specific quantitative reverse transcription polymerase chain reaction (RT-qPCR) tests developed in partnership with a private company was a strategic advantage in Türkiye, given the scarcity and fragmented global supply chain early in the pandemic. Türkiye contributed more than 86,000 genomic sequences to global databases by February 2022, ensuring that Turkish data was reflected globally. The synergy of variant-specific RT-qPCR kits and genomic sequencing enabled cost-effective monitoring of VOCs. However, data analysis was constrained by a weak sequencing sampling strategy and fragmented data management systems, limiting the application of sequencing data to guide the public health response. Phylodynamic analysis indicated that Türkiye's geographical position as an international travel hub influenced both national and global transmission of each VOC despite travel restrictions.
Conclusion UNASSIGNED
This paper provides valuable insights into the testing and genomic surveillance systems adopted by Türkiye during the COVID-19 pandemic, proposing important lessons for countries developing national systems. The findings underscore the need for robust testing and sampling strategies, streamlined sample referral, and integrated data management with metadata linkage and data quality crucial for impactful epidemiological analysis. We recommend developing national genomic surveillance strategies to guide sustainable and integrated expansion of capacities built for COVID-19 and to optimize the effective utilization of sequencing data for public health action.

Identifiants

pubmed: 38855447
doi: 10.3389/fpubh.2024.1332109
pmc: PMC11160438
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1332109

Informations de copyright

Copyright © 2024 Yalçın, Coşgun, Dedeoğlu, Kopp, Bayrakdar, Ünal, Musul, Sağtaş, Korukluoğlu, Raftery and Kaygusuz.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Süleyman Yalçın (S)

National Molecular Microbiology Reference Laboratory, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.
Department of National Reference Laboratories and Biological Products, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.

Yasemin Coşgun (Y)

Department of National Reference Laboratories and Biological Products, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.
National Virology Reference Laboratory, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.

Ege Dedeoğlu (E)

World Health Organization Country Office, Ankara, Türkiye.

Katharina Kopp (K)

World Health Organization Country Office, Ankara, Türkiye.

Fatma Bayrakdar (F)

National Molecular Microbiology Reference Laboratory, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.
Department of National Reference Laboratories and Biological Products, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.

Gültekin Ünal (G)

World Health Organization Country Office, Ankara, Türkiye.

Biran Musul (B)

World Health Organization Country Office, Ankara, Türkiye.

Ekrem Sağtaş (E)

Department of National Reference Laboratories and Biological Products, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.

Gülay Korukluoğlu (G)

Department of Medical Microbiology, University Health Sciences, Ankara Bilkent City Hospital, Ankara, Türkiye.

Philomena Raftery (P)

World Health Organization Country Office, Ankara, Türkiye.

Sedat Kaygusuz (S)

Public Health General Directorate, Ministry of Health, Ankara, Türkiye.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH